Subscribe to our newsletter

Rebecca Ashfield

Senior Project Manager, Jenner Institute, University of Oxford

I studied at the University of Oxford, and have 20 years' experience in immunotherapy research, spanning academia and industry.

I worked for 12 years at Immunocore Ltd developing immunotherapeutics for cancer, and in 2013 returned to the University of Oxford where I work at the Jenner Institute, managing translational vaccine projects.

Since 2015 I have been the CSO of Ducentis Biotherapeutics Ltd, developing novel therapies for autoimmune disease and inflammation.

I am an external consultant in the fields of vaccine development including GMP manufacture, and cancer immunotherapy.

Follow Rebecca:

From This Author

Oxford Scientists: These Are Final Steps We’re Taking to Get Our Coronavirus Vaccine Approved

Of the hundreds of potential Covid-19 vaccines in development, six are in the final stages of testing, known as phase three clinical trials. One of these—ChAdOx1 nCoV-19—is the vaccine we’re developing at the University...

Singularity University, Singularity Hub, Singularity Summit, SU Labs, Singularity Labs, Exponential Medicine, Exponential Finance and all associated logos and design elements are trademarks and/or service marks of Singularity Education Group.

© 2021 Singularity Education Group. All Rights Reserved.

Singularity University is not a degree granting institution.